nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2016-4-71-76nnp-676Research ArticleREVIEWSОБЗОРЫPOSTSTROKE SPASTICITY: AN INDIVIDUALIZED APPROACH TO TREATMENTПОСТИНСУЛЬТНАЯ СПАСТИЧНОСТЬ, ИНДИВИДУАЛИЗИРОВАННЫЙ ПОДХОД К ЛЕЧЕНИЮТолмачеваВ. А.TolmachevaV. A.

Виолетта Александровна Толмачева - кафедра нервных болезней и нейрохирургии.

119021, Москва, ул. Россолимо, 11, vtolmacheva@yandex.ru

Violetta Aleksandrovna Tolmacheva - Department of Nervous System Diseases and Neurosurgery.

11, Rossolimo St., Moscow 119021, vtolmacheva@yandex.ru

vtolmacheva@yandex.ruПервый Московский государственный медицинский университет имени И.М. СеченоваРоссияI.M. Sechenov First Moscow State Medical UniversityRussian Federation201616122016847176Copyright © Tolmacheva V.A., 20162016Толмачева В.А.Tolmacheva V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/676

Poststroke spasticity is common in many patients and frequently hampers the recovery of lost motor functions. Therapeutic exercises and a gradual increase in motion loads and social and daily living activities play a leading role in the treatment of spasticity. Botulinium toxin type A is recognized to offer a highly effective and safe treatment for poststroke spasticity, as confirmed by clinical trials conducted in accordance with the principles of evidence-based medicine. The application of a personalized poststroke rehabilitation program permits the maximum result to be achieved in a considerable number of patients. The paper reviews the literature on spasticity and a clinical case that demonstrates an individual approach to treating poststroke spasticity.

Постинсультная спастичность встречается у многих пациентов и часто затрудняет восстановление утраченных двигательных функций. Ведущее значение в лечении спастичности имеют лечебная гимнастика, постепенное увеличение двигательных нагрузок, социальной и бытовой активности. Высокоэффективным и безопасным методом лечения постинсультной спастичности признано использование ботулининического токсина типа А, что подтверждено данными клинических исследований, проведенных в соответствии с принципами доказательной медицины. Использование индивидуальной программы постинсультной реабилитации позволяет добиться максимального результата у значительного числа больных. Представлены обзор литературы, посвященной спастичности, и клиническое наблюдение, демонстрирующее индивидуальный подход к лечению постинсультной спастичности.

инсультреабилитацияпостинсультная спастичностьботулинический токсин типа Аstrokerehabilitationpoststroke spasticitybotulinum toxin type AReferencesEuropean Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischemic stroke and transient ischemic attack. Cerebrovasc Dis. 2008;25(5):457-507. doi: 10.1159/000131083. Epub 2008 May 6.European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischemic stroke and transient ischemic attack. Cerebrovasc Dis. 2008;25(5):457-507. doi: 10.1159/000131083. Epub 2008 May 6.Гусев ЕИ, Скворцова ВИ. Ишемия головного мозга. Москва: Медицина; 2001. 328 с. [Gusev EI, Skvortsova VI. Ishemiya golovnogo mozga [Cerebral ischemia]. Moscow: Meditsina; 2001. 328 p.]Гусев ЕИ, Скворцова ВИ. Ишемия головного мозга. Москва: Медицина; 2001. 328 с. [Gusev EI, Skvortsova VI. Ishemiya golovnogo mozga [Cerebral ischemia]. Moscow: Meditsina; 2001. 328 p.]Епифанов ВА, Епифанов АВ. Реабилитация больных, перенесших инсульт. Москва: МЕДпресс-информ; 2013. 243 с. [Epifanov VA, Epifanov AV. Reabilitatsiya bol'nykh, perenesshikh insul't [Rehabilitation of patients with stroke]. Moscow: MEDpressinform; 2013. 243 p.]Епифанов ВА, Епифанов АВ. Реабилитация больных, перенесших инсульт. Москва: МЕДпресс-информ; 2013. 243 с. [Epifanov VA, Epifanov AV. Reabilitatsiya bol'nykh, perenesshikh insul't [Rehabilitation of patients with stroke]. Moscow: MEDpressinform; 2013. 243 p.]Скворцова ВИ, Губский ЛВ, Стаховская ЛВ и др. Ишемический инсульт. В кн.: Гусев ЕИ, Коновалов АИ, Скворцова ВИ, редакторы. Неврология, национальное руководство. Москва: Гэотар-медиа; 2009. С. 592-615. [Skvortsova VI, Gubskii LV, Stakhovskaya LV, et al. Ischemic stroke. In: Gusev EI, Konovalov AI, Skvortsova VI, editors. Nevrologiya, natsional'noe rukovodstvo [Neurology. A national guide]. Moscow: Geotar-media; 2009. P. 592-615.]Скворцова ВИ, Губский ЛВ, Стаховская ЛВ и др. Ишемический инсульт. В кн.: Гусев ЕИ, Коновалов АИ, Скворцова ВИ, редакторы. Неврология, национальное руководство. Москва: Гэотар-медиа; 2009. С. 592-615. [Skvortsova VI, Gubskii LV, Stakhovskaya LV, et al. Ischemic stroke. In: Gusev EI, Konovalov AI, Skvortsova VI, editors. Nevrologiya, natsional'noe rukovodstvo [Neurology. A national guide]. Moscow: Geotar-media; 2009. P. 592-615.]Парфенов ВА. Спастичность. В кн.: Орлова ОР, Яхно НН, редакторы. Применение ботокса (токсина ботулизма типа А)ив клинической практике: руководство дляиврачей. Москва: Каталог; 2001. С. 91-122. [Parfenov VA. Spasticity. In: Orlova OR, Yakhno NN, editors. Primenenie botoksa (toksina botulizma tipa A) v klinicheskoi praktike:иrukovodstvo dlya vrachei [The use of Botoxи(botulinum toxin type A) in clinical practice: a guide for physicians]. Moscow: Katalog; 2001. P. 91-122.]Парфенов ВА. Спастичность. В кн.: Орлова ОР, Яхно НН, редакторы. Применение ботокса (токсина ботулизма типа А)ив клинической практике: руководство дляиврачей. Москва: Каталог; 2001. С. 91-122. [Parfenov VA. Spasticity. In: Orlova OR, Yakhno NN, editors. Primenenie botoksa (toksina botulizma tipa A) v klinicheskoi praktike:иrukovodstvo dlya vrachei [The use of Botoxи(botulinum toxin type A) in clinical practice: a guide for physicians]. Moscow: Katalog; 2001. P. 91-122.]Парфенов ВА, Хасанова ДР. Ишемический инсульт. Москва: МИА; 2012. 288 с. [Parfenov VA, Khasanova DR. Ishemicheskii insul't [Ischemic stroke]. Moscow: MIA; 2012. 288 p.]Парфенов ВА, Хасанова ДР. Ишемический инсульт. Москва: МИА; 2012. 288 с. [Parfenov VA, Khasanova DR. Ishemicheskii insul't [Ischemic stroke]. Moscow: MIA; 2012. 288 p.]Кадыков АС, Черникова ЛА, Шахпаронова НВ. Реабилитация неврологических больных. Москва: МЕДпресс-информ; 2015. 560 с. [Kadykov AS, Chernikova LA, Shakhparonova NV. Reabilitatsiya nevrologicheskikh bol'nykh [Rehabilitation of neurological patients]. Moscow: MEDpress-inform; 2015. 560 p.]Кадыков АС, Черникова ЛА, Шахпаронова НВ. Реабилитация неврологических больных. Москва: МЕДпресс-информ; 2015. 560 с. [Kadykov AS, Chernikova LA, Shakhparonova NV. Reabilitatsiya nevrologicheskikh bol'nykh [Rehabilitation of neurological patients]. Moscow: MEDpress-inform; 2015. 560 p.]Mayer NH. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle Nerve. Suppl. 1997;6:S1-13.Mayer NH. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle Nerve. Suppl. 1997;6:S1-13.Gracies JM. Pathophysiology of spastic paresis. II: Emergence of muscle overactivity. Muscle Nerve. 2005 May;31(5):552-71.Gracies JM. Pathophysiology of spastic paresis. II: Emergence of muscle overactivity. Muscle Nerve. 2005 May;31(5):552-71.Lance JW. Symposium synopsis, in Spasticity: Disordered Motor Control., Feldman RG, Young RR, Koella WP, Editors. Chicago: Year Book Medical Publishers; 1980. P. 485–94.Lance JW. Symposium synopsis, in Spasticity: Disordered Motor Control., Feldman RG, Young RR, Koella WP, Editors. Chicago: Year Book Medical Publishers; 1980. P. 485–94.Завалишин ИА. Спастичность. Русский медицинский журнал. 2004;(5):261-6. [Zavalishin IA. Spasticity. Russkii meditsinskii zhurnal. 2004;(5):261-6. (In Russ.)].Завалишин ИА. Спастичность. Русский медицинский журнал. 2004;(5):261-6. [Zavalishin IA. Spasticity. Russkii meditsinskii zhurnal. 2004;(5):261-6. (In Russ.)].Райхель Г. Терапевтическое руководство спастичность – дистонии. 1-е изд. Бремен: УНИ-МЕД; 2013. C. 12–3. [Raikhel' G. Terapevticheskoe rukovodstvo spastichnost' – distonii [Therapeutic guide spasticity – dystonia]. 1st ed. Bremen: UNI-MED; 2013. P. 12–3.]Райхель Г. Терапевтическое руководство спастичность – дистонии. 1-е изд. Бремен: УНИ-МЕД; 2013. C. 12–3. [Raikhel' G. Terapevticheskoe rukovodstvo spastichnost' – distonii [Therapeutic guide spasticity – dystonia]. 1st ed. Bremen: UNI-MED; 2013. P. 12–3.]Парфенов ВА. Патогенез и лечение спастичности. Русский медицинский журнал. 2001;(25):1170-4. [Parfenov VA. Pathogenesis and treatment of spasticity. Russkii meditsinskii zhurnal. 2001;(25):1170-4. (In Russ.)].Парфенов ВА. Патогенез и лечение спастичности. Русский медицинский журнал. 2001;(25):1170-4. [Parfenov VA. Pathogenesis and treatment of spasticity. Russkii meditsinskii zhurnal. 2001;(25):1170-4. (In Russ.)].Парфенов ВА. Постинсультная спастичность. Лечащий врач. 2008;(5):34–8. [Parfenov VA. Postinsul'tnaya spastichnost' [Post-stroke spasticity]. Lechashchii vrach. 2008;(5):34–8. (In Russ.)].Парфенов ВА. Постинсультная спастичность. Лечащий врач. 2008;(5):34–8. [Parfenov VA. Postinsul'tnaya spastichnost' [Post-stroke spasticity]. Lechashchii vrach. 2008;(5):34–8. (In Russ.)].Gracies JM. Pathophysiology of spastic paresis. I: Paresis and soft tissue changes. Muscle Nerve. 2005 May;31(5):535-51.Gracies JM. Pathophysiology of spastic paresis. I: Paresis and soft tissue changes. Muscle Nerve. 2005 May;31(5):535-51.Катушкина ЭА, Зиновьева ОЕ, Яхно НН и др. Постинсультная спастичность: нейрофизиологические характеристики состояния верхнего и нижнего мотонейронов. Неврологический журнал. 2011;16(4):11–8. [Katushkina EA, Zinov'eva OE, Yakhno NN, et al. Post-stroke spasticity: neurophysiologic features of state of upper and lower motoneurons. Nevrologicheskii zhurnal. 2011;16(4):11–8. (In Russ.)].Катушкина ЭА, Зиновьева ОЕ, Яхно НН и др. Постинсультная спастичность: нейрофизиологические характеристики состояния верхнего и нижнего мотонейронов. Неврологический журнал. 2011;16(4):11–8. [Katushkina EA, Zinov'eva OE, Yakhno NN, et al. Post-stroke spasticity: neurophysiologic features of state of upper and lower motoneurons. Nevrologicheskii zhurnal. 2011;16(4):11–8. (In Russ.)].Emre M, Leslie GC, Muir C, et al. Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud). J Neurol Neurosurg Psychiatry. 1994 Nov;57(11):1355-9.Emre M, Leslie GC, Muir C, et al. Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud). J Neurol Neurosurg Psychiatry. 1994 Nov;57(11):1355-9.Urban PP, Wolf T, Uebele M, et al. Occurence and clinical predictors of spasticity after ischemic stroke. Stroke. 2010 Sep;41(9):2016-20. doi: 10.1161/STROKEHA.110.581991. Epub 2010 Aug 12.Urban PP, Wolf T, Uebele M, et al. Occurence and clinical predictors of spasticity after ischemic stroke. Stroke. 2010 Sep;41(9):2016-20. doi: 10.1161/STROKEHA.110.581991. Epub 2010 Aug 12.Lundströ m E, Smits A, Terent A, Borg J. Time-course and determinants of spasticity during the first six month following first-ever stroke. J Rehabil Med. 2010 Apr;42(4):296-301. doi: 10.2340/16501977-0509.Lundströ m E, Smits A, Terent A, Borg J. Time-course and determinants of spasticity during the first six month following first-ever stroke. J Rehabil Med. 2010 Apr;42(4):296-301. doi: 10.2340/16501977-0509.Wissel J, Schelosky LD, Scott J, et al. Early development of spasticity following stroke: a prospective, observational trial. J Neurol. 2010 Jul;257(7):1067-72. doi: 10.1007/s00415-010-5463-1. Epub 2010 Feb 6.Wissel J, Schelosky LD, Scott J, et al. Early development of spasticity following stroke: a prospective, observational trial. J Neurol. 2010 Jul;257(7):1067-72. doi: 10.1007/s00415-010-5463-1. Epub 2010 Feb 6.Sommerfeld DK, Eek EU, Svensson AK, et al. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke. 2004 Jan;35(1):134-9. Epub 2003 Dec 18.Sommerfeld DK, Eek EU, Svensson AK, et al. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke. 2004 Jan;35(1):134-9. Epub 2003 Dec 18.Хатькова СЕ, Орлова ОР, Тимербаева СЛ. Оценка клинического профиля взрослых пациентов со спастичностью верхней конечности, которым показаны инъекции ботулинического токсина типа А (по данным международного исследования). Журнал неврологии и психиатрии им. С.С.Корсакова. 2011;(8):23–6. [Khat'kova SE, Orlova OR, Timerbaeva SL. Assessment of the clinical profile of adult patients with spasticity of the upper limb, which shows the injection of botulinum toxin type A (according to international survey). Zhurnal nevrologii i psikhiatrii im. S.S.Korsakova. 2011;(8):23-6. (In Russ.)].Хатькова СЕ, Орлова ОР, Тимербаева СЛ. Оценка клинического профиля взрослых пациентов со спастичностью верхней конечности, которым показаны инъекции ботулинического токсина типа А (по данным международного исследования). Журнал неврологии и психиатрии им. С.С.Корсакова. 2011;(8):23–6. [Khat'kova SE, Orlova OR, Timerbaeva SL. Assessment of the clinical profile of adult patients with spasticity of the upper limb, which shows the injection of botulinum toxin type A (according to international survey). Zhurnal nevrologii i psikhiatrii im. S.S.Korsakova. 2011;(8):23-6. (In Russ.)].Bakheit AM, Zakine B, Maisonobe P, et al. The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type a: an international survey. Int J Rehabil Res. 2010 Sep;33(3):199-204. doi: 10.1097/MRR.0b013e328332f5e0.Bakheit AM, Zakine B, Maisonobe P, et al. The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type a: an international survey. Int J Rehabil Res. 2010 Sep;33(3):199-204. doi: 10.1097/MRR.0b013e328332f5e0.Wissel J, Verrier M, Simpson DM, et al. Post-stroke spasticity: predictors of early development and considerations for therapeutic intervention. PM R. 2015 Jan;7(1):60-7. doi: 10.1016/j.pmrj.2014.08.946. Epub 2014 Aug 27.Wissel J, Verrier M, Simpson DM, et al. Post-stroke spasticity: predictors of early development and considerations for therapeutic intervention. PM R. 2015 Jan;7(1):60-7. doi: 10.1016/j.pmrj.2014.08.946. Epub 2014 Aug 27.Francisco GE, McGuire JR. Poststroke spasticity management. Stroke. 2012 Nov;43(11):3132-6. doi: 10.1161/STROKEAHA.111.639831. Epub 2012 Sep 13.Francisco GE, McGuire JR. Poststroke spasticity management. Stroke. 2012 Nov;43(11):3132-6. doi: 10.1161/STROKEAHA.111.639831. Epub 2012 Sep 13.Rosales RL, Kong KH, Goh KJ, et al. Botulinum toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke: a randomized controlled trial. Neurorehabil Neural Repair. 2012 Sep;26(7): 812-21. doi: 10.1177/1545968311430824. Epub 2012 Feb 27.Rosales RL, Kong KH, Goh KJ, et al. Botulinum toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke: a randomized controlled trial. Neurorehabil Neural Repair. 2012 Sep;26(7): 812-21. doi: 10.1177/1545968311430824. Epub 2012 Feb 27.Данилов АБ, Давыдов ОС. Центральная нейропатическая боль: клинико-диагностические аспекты и возможности терапии на основе доказательств. Неврология и ревматология. 2009;(1):60-4. [Danilov AB, Davydov OS. Central neuropathic pain: clinical and diagnostic aspects and therapeutic options based on evidence. Nevrologiya i revmatologiya. 2009;(1): 60-4. (In Russ.)].Данилов АБ, Давыдов ОС. Центральная нейропатическая боль: клинико-диагностические аспекты и возможности терапии на основе доказательств. Неврология и ревматология. 2009;(1):60-4. [Danilov AB, Davydov OS. Central neuropathic pain: clinical and diagnostic aspects and therapeutic options based on evidence. Nevrologiya i revmatologiya. 2009;(1): 60-4. (In Russ.)].Bakheit M. Botulinum toxin treatment of muscle spasticity. 2nd ed. AuthorHouse; 2007. 216 p.Bakheit M. Botulinum toxin treatment of muscle spasticity. 2nd ed. AuthorHouse; 2007. 216 p.Ward AB. Handbook of the management of adult spasticity course. Stoke on Trent; 2008. 264 p.Ward AB. Handbook of the management of adult spasticity course. Stoke on Trent; 2008. 264 p.Elovic E, Brashear A. Spasticity: Diagnosis and Management. 1st ed. Demos Medical Publishing; 2010. 412 p.Elovic E, Brashear A. Spasticity: Diagnosis and Management. 1st ed. Demos Medical Publishing; 2010. 412 p.Barnes MP, Johnson GR. UMN syndrome and spasticity. Cambridge University Press; 2008.Barnes MP, Johnson GR. UMN syndrome and spasticity. Cambridge University Press; 2008.Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016 May 10;86(19): 1818-26. doi: 10.1212/WNL.0000000000002560. Epub 2016 Apr 18.Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016 May 10;86(19): 1818-26. doi: 10.1212/WNL.0000000000002560. Epub 2016 Apr 18.Autti-Ramo J, Larsen T, Peltonen J. The use of botulinum toxin treatment in children with movement disorders. Eur J Neurol. 2007;(4):23-6.Autti-Ramo J, Larsen T, Peltonen J. The use of botulinum toxin treatment in children with movement disorders. Eur J Neurol. 2007;(4):23-6.Royal M. The use of botulinum toxin in the management of myofascial pain and other conditions associated with painful muscle spasm. In: Brin M, Jankovic J, Hallet M, editors. Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia: Lippincott Williams & Wilkins; 2002. 204 p.Royal M. The use of botulinum toxin in the management of myofascial pain and other conditions associated with painful muscle spasm. In: Brin M, Jankovic J, Hallet M, editors. Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia: Lippincott Williams & Wilkins; 2002. 204 p.Olvey EL, Armstrong EP, Grizzle AJ. Contemporary pharmacologic treatments for spasticity of the upper limb after stroke: a systematic review. Clin Ther. 2010 Dec;32(14): 2282-303. doi: 10.1016/j.clinthera.2011.01.005.Olvey EL, Armstrong EP, Grizzle AJ. Contemporary pharmacologic treatments for spasticity of the upper limb after stroke: a systematic review. Clin Ther. 2010 Dec;32(14): 2282-303. doi: 10.1016/j.clinthera.2011.01.005.Foley N, Murie-Fernandez M, Speechley M, et al. Does the treatment of spastic equinovarus deformity following stroke with botulinum toxin increase gait velocity? A systematic review and meta-analysis. Eur J Neurol. 2010 Dec;17(12): 1419-27. doi: 10.1111/j.1468-1331.2010.03084.x.Foley N, Murie-Fernandez M, Speechley M, et al. Does the treatment of spastic equinovarus deformity following stroke with botulinum toxin increase gait velocity? A systematic review and meta-analysis. Eur J Neurol. 2010 Dec;17(12): 1419-27. doi: 10.1111/j.1468-1331.2010.03084.x.Kaji R, Osako Y, Suyama K, et al. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol. 2010 Aug; 257(8):1330-7. doi: 10.1007/s00415-010-5526-3. Epub 2010 Apr 1.Kaji R, Osako Y, Suyama K, et al. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol. 2010 Aug; 257(8):1330-7. doi: 10.1007/s00415-010-5526-3. Epub 2010 Apr 1.Pittock SJ, Moore AP, Hardiman O, et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis. 2003;15(4):289-300.Pittock SJ, Moore AP, Hardiman O, et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis. 2003;15(4):289-300.Santamato A, Micello MF, Panza F, et al. Safety and efficacy of incobotulinum toxin type A (NT 201-Xeomin) for the treatment of poststroke lower limb spasticity: a prospective openlabel study. Eur J Phys Rehabil Med. 2013 Aug;49(4):483-9. Epub 2013 Mar 13.Santamato A, Micello MF, Panza F, et al. Safety and efficacy of incobotulinum toxin type A (NT 201-Xeomin) for the treatment of poststroke lower limb spasticity: a prospective openlabel study. Eur J Phys Rehabil Med. 2013 Aug;49(4):483-9. Epub 2013 Mar 13.Santamato A, Panza F, Ranieri M, et al. Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexina proteins in the upper and lower limb spasticity after stroke. J Neural Transm (Vienna). 2013 Mar;120(3):469-76. doi: 10.1007/s00702-012-0892-x. Epub 2012 Sep 7.Santamato A, Panza F, Ranieri M, et al. Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexina proteins in the upper and lower limb spasticity after stroke. J Neural Transm (Vienna). 2013 Mar;120(3):469-76. doi: 10.1007/s00702-012-0892-x. Epub 2012 Sep 7.

The authors declare that there are no conflicts of interest present.